Anjarium Biosciences names new chief executive officer
15 June 2022 -

Anjarium Biosciences AG, a Swiss-based biotech company focused on creating and delivering a new class of non-viral gene therapies, announced on Tuesday that it has named Stephen Yoo, MD as its new chief executive officer (CEO).

Yoo has worked in the industry for 14 years. He has served as chief medical officer (CMO) and head of R&D at Third Harmonic Bio. He has held various roles in clinical development at MedImmune/AstraZeneca and at Abbott Labs within the autoimmunity and inflammation Group.

Bali Muralidhar, managing partner at investment company Abingworth and director at Anjarium, said: "We're delighted to be bringing Stephen on board as Anjarium's CEO. His appointment marks an important milestone for the company as we leverage the success of our CHF55.5 M (USD61M) Series A round to advance our ground-breaking platform and progress therapeutic pipeline programs towards clinical development. His broad experience in building small companies and his knowledge of the gene therapy space make Stephen the perfect candidate to steer Anjarium through the next stages of its growth."